Clinical Trials Browser

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Unknown

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Phase 2 Unknown

45 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Phase 2 Unknown

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 2 Unknown

21 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Phase 1/2 Unknown

88 enrolled

Head & Neck

Head and Neck Squamous Cell Cancer

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Phase 2 Unknown

61 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 1 Unknown

41 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

32 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04995120 2022-01-18

INSIGHT

Phase 2 Unknown

42 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Phase 2 Unknown

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

14 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04947241 2021-07-01

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04926753 2021-06-16

Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer

Phase 1 Unknown

20 enrolled

Head & Neck

Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer

NCT04523883 2021-04-15

IMPORT

Phase 2 Unknown

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04624308 2020-11-10

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

Phase 2 Unknown

81 enrolled

Head & Neck

Hypopharyngeal Neoplasms

NCT04524884 2020-08-24

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Phase 2 Unknown

10 enrolled

Head & Neck

Thyroid Neoplasms

NCT04164238 2019-11-15

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Phase 2 Unknown

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04126460 2019-10-15

RePASS

Phase 2 Unknown

41 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence